Advanced Micro Devices joining the trillion-dollar club signals AI infrastructure spending has a second major winner

Advanced Micro Devices shares rocketed to record highs Monday, pushing the chipmaker past a $1 trillion market value and making it only the 14th American company ever to reach that threshold, fueled by growing conviction that its chips are becoming essential to the AI computing boom.

The real story is not the round number but what it says about how AI workloads are spreading: investors are betting that the AI buildout is big enough to mint more than one dominant chip supplier, and Advanced Micro Devices is now their clearest proof of concept.

The reimbursement fight, not FDA approval, is the real obstacle for Grail's cancer blood test

Shares of Grail's parent company soared more than 33% after FDA staff reviewers published documents ahead of Wednesday's advisory panel meeting, raising no major red flags about the accuracy or safety of the Galleri test, which screens for multiple cancers from a single blood draw.

FDA approval would be a landmark moment, but whether insurers agree to pay for the test will ultimately determine whether Galleri becomes a routine screening tool or an expensive option available only to those who can afford it out of pocket.

Novo Nordisk's bold 2030 pipeline plan failed to convince investors it has a story beyond weight loss

The Danish drugmaker laid out an ambitious roadmap at its investor day, promising more than five major drug launches by 2030 and outperforming Eli Lilly's rival obesity treatment in late-stage trials, yet the stock fell sharply despite the strong clinical news.

The stock's sharp drop tells you the market wanted a reinvention narrative, not an extension of the same obesity franchise, and until Novo can show it has a genuinely diversified engine of growth, the weight-loss drug story will remain both its greatest asset and its biggest liability.